My Bio: Peyton Elizabeth Beck

Date:	12/08/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	El Paso Children's Hospital, Preceptor: Dr. Denise Pinal
Comments:	Cystic Fibrosis: Pediatric Population Topic Discussion

View

My Bio: Peyton Elizabeth Beck
Hello potential employer! Thank you for taking interest in me as a potential candidate. My name is Peyton Beck, and I am currently a fourth year pharmacy student at the University of Texas at El Paso School of Pharmacy. Before pharmacy school, I grew up in St. Louis, Missouri, and completed my undergraduate degree in New York City while playing Division I college soccer. Upon graduation, I am looking for opportunities to be a problem solver, mentor, creator, and advocate within our health care system. I am highly motivated to make change, lead, and conduct necessary tasks to improve pharmacy business operations, collaboration efforts, and public health disparities. These passions allude to my Strengths Finder and 5Voices personalities: Connector, Relator, Creator, Achiever, Input, and Communication. Please do not hesitate in reaching out to me via phone or email!

My Bio: Peyton Elizabeth Beck

Peyton Beck
PharmD Candidate Class of 2023 
University of Texas at El Paso School of Pharmacy
pebeck@miners.utep.edu
314-974-6828
1831 Murchison Drive Apt 112
El Paso, TX 79902

 

Resume & CV: Peyton Elizabeth Beck
P_Beck_CV (.pdf) 0.09mb

Affiliations (Universities & Colleges): Peyton Elizabeth Beck
Doctor of Pharmacy Candidate, expected May 2023
Current GPA of 3.78 with 136 earned credit hours

Affiliations (Universities & Colleges): Peyton Elizabeth Beck
August 2015 to May 2019
Staten Island, New York
B.S. in Biopsychology degree with minor in Chemistry
Conferred as Magna Cum Laude with 3.85 GPA

Transcripts: Peyton Elizabeth Beck
UTEP Unofficial Transcript 2022 (.pdf) 1.15mb

Transcripts: Peyton Elizabeth Beck
Undergraduate Unofficial Transcript (.pdf) 0.01mb

Internships: Peyton Elizabeth Beck
September 2020 – Present
Emergence Health Network & Project Vida Health Center – El Paso, TX
Supervisors: Steven Romero, RPh, Crystal Delgado, RPh, Nestor Gaytan, RPh, & Andre Montes, PharmD, BCPP

Developed skills in patient counseling, patient assistance program consultations, and 340(B) pharmacy services

Employment History: Peyton Elizabeth Beck

February 2022 – Present 
Texas Tech University Health Sciences Center at El Paso – El Paso, TX
Supervisor: Stormy Monks, PhD, MPH, CHES

Responsible for the operations of clinical research projects for the department, along with recruiting and enrolling human subjects

Employment History: Peyton Elizabeth Beck

May 2017 – July 2022
Corum Health Services, Inc. – St. Louis, MO
Supervisor: Steve Hebel, RPh, Executive Director

Developed skills in non-sterile compounding, IV production, hospice care, long term care, and OTC proficiency 

Employment History: Peyton Elizabeth Beck

August 2018 – May 2019
Delco Drugs & Specialty Pharmacy – Staten Island, NY 
Supervisor: Arif Ramush, RPh

Field experience for Bachelor’s degree dissertation: “The Importance of Emotional Intelligence in the Field of Pharmacy”

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck

April 2023 – May 2023
Genoa Healthcare – El Paso, TX
Preceptor: Andre Montes, PharmD, BCPP

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck

February 2023 – March 2023
University Medical Center of El Paso – El Paso, TX
Preceptor: Alejandro Moreno, PharmD

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck

January 2023 – February 2023
The Hospitals of Providence East Campus – El Paso, TX
Preceptor: Lauren Ramos, PharmD

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck

November 2022 – December 2022
El Paso Children’s Hospital – El Paso, TX
Preceptor: Denise Pinal, PharmD, BCPPS

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck

August 2022 – September 2022
El Paso Veterans Affairs Healthcare System – El Paso, TX
Preceptors: Janice Miller, PharmD, BCACP & Dean Jan, PharmD

Conducted centralized anticoagulation management services, performed daily therapeutic drug monitoring, and clarified orders with providers

Rounded with PACT clinical pharmacy specialists in primary care, psychiatric care, and administrative roles

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck

July 2022 – August 2022

Socorro Independent School District (SISD) Employee Health Clinic – El Paso, TX
Preceptor: Eric Garcia, PharmD

Performed counselings in English and Spanish, minimized medication errors, and oversaw pharmacy operations for multiple shifts under preceptor supervision

Collaborated with SISD providers and executive board members to enhance the clinic’s public health promotion and cost-effectiveness

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck

May 2022 – July 2022
Premier Specialty Hospital of El Paso – El Paso, TX
Preceptor: Mikhil Adusumilli, PharmD, Director of Pharmacy

Daily rounds with LTAC interdisciplinary team, clinical monitoring management, and pharmacotherapy interventions

Rounded with pharmacists in affiliated ASC facility and administrative roles

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck

April 2022 – May 2022
The Hospitals of Providence Memorial Campus – El Paso, TX
Preceptor: Clarissa Enriquez-Ahearn, PharmD

Shadowed pharmacists and nurses in facility’s outpatient oncology clinic

In-service presentation provided: “The Need for Precision Medicine in Psychiatry”

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck

January 2022
Memorial Medical Center – Las Cruces, NM
Shadowed: Jeremiah Oltmanns, PharmD

Gained knowledge in oncology, geriatrics, and palliative care from witnessing the workflow of an outpatient oncology clinic

In-service presentation provided: “Paxlovid vs. Molnupiravir: COVID-19 EUA Drugs”

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck

November 2021 – February 2022
CVS #11020 – El Paso, TX 
Preceptor: Erica McFarland, RPh

Conducted MTM reviews in English and Spanish, administered vaccines, and performed patient counseling 

Clinicals / Clerkships / Externships: Peyton Elizabeth Beck
This log is currently up to date with my completed PharmD student hours. It is a total of approx. 1,117 hours towards graduation. This log contains rotation dates, preceptor & site information, and some personal descriptions of the experiences.  UTEP Student Hours 2019 - 2022 (.pdf) 0.44mb

Interprofessional Education (IPE): Peyton Elizabeth Beck

Date:	01/20/2023
Rotation Type:	P4 P6685 InPt Gen Med APPE
Comments:
Provide a summary of your IPE activity:	Dr. Ramos and I responded to a Code Blue on Friday night, 01/20/23. In this critical situation, I communicated with various nurses, physicians, and scribes to exercise emergency patient care. Dr. Ramos and I were tasked with the management of crash cart supplies and confirmation of medication administrations. Additionally, we verbally verified patient-specific indications and dosages with the team prior to administrations.

Interprofessional Education (IPE): Peyton Elizabeth Beck

Date:	01/07/2022
Rotation Type:	P3Su P6281 Hospital Course IPPE
What are that interprofessional team member's activities/responsibilities?:	Complete tasks regarding daily patient list and treatment plans. Communicate with physicians and pharmacists to implement approved medication regimens. Pull and administer medications for each patient. Also support with palliative care and non-pharmacology strategies, when needed.
What are the overlapping activities/responsibilities between pharmacy and the interprofessional team member?:	Overlapping activities include assessing the patient's profile and status to get current treatment approved by physician. Both communicate with patient's physician regarding clarifications/updates on patient status (labs, physical assessment, adverse effects) to verify appropriateness of the current medication regimen.
Which member of the interprofessional team did you shadow?:	Oncology Certified Nurse (OCN), Kristina
What are that interprofessional team member's activities/responsibilities?:	The technicians fill medication orders to be distributed throughout the hospital. They update the omnicell machines throughout the pharmacy, and count for their inventory discrepancies. The techs put away the main inventory and keep track of orders and drug shortages. They fill crash carts and other kits. They are able to give vaccines. They deliver controls, expensive medications, and hazardous medications to the appropriate nurse due to required signatures. They make IVs, mixed solutions, and compounds.
What are the overlapping activities/responsibilities between pharmacy and the interprofessional team member?:	Maintaining inventories and strategizing during drug shortages. General knowledge of medications and how they are individually dispensed. General knowledge of workflow and required distribution times within hospital. IV and controlled substances procedures.
Which member of the interprofessional team did you shadow?:	Pharmacy technician, Salma

Presentations: Peyton Elizabeth Beck

Date:	01/20/2023
Rotation Type:	P4 P6685 InPt Gen Med APPE
Comments:	THOP - East Campus, Dr. Lauren Ramos
Comments:	Pneumonia Topic Discussion & Follow-up Questions

View

Presentations: Peyton Elizabeth Beck

Date:	12/14/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	El Paso Children's Hospital, Dr. Denise Pinal
Comments:	Final Presentation: Anorexia Nervosa in the Pediatric Population

View

Presentations: Peyton Elizabeth Beck

Date:	12/13/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	El Paso Children's Hospital, Dr. Denise Pinal
Comments:	Formal Patient Case Presentation: Complicated UTIs & Pyelonephritis in the Pediatric Population

View

Presentations: Peyton Elizabeth Beck

Date:	11/18/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	Presented to preceptor & colleagues at El Paso Children's Hospital
Comments:	Bacterial Meningitis: Pediatric Population Topic Discussion Presentation

View

Presentations: Peyton Elizabeth Beck

Date:	11/15/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	Presented to Dr. Pinal & Colleagues at El Paso Children's Hospital
Comments:	Pediatric RSV Bronchiolitis Topic Discussion Presentation

View

Presentations: Peyton Elizabeth Beck

Date:	09/21/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Comments:	Transition of Care Initiatives

View

Presentations: Peyton Elizabeth Beck

Date:	09/22/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Comments:	Illicit Drug & Cannabis Use Final Presentation

View

Presentations: Peyton Elizabeth Beck
Presented 09/15/22 MDD, GAD, & PTSD (.pdf) 4.59mb

Presentations: Peyton Elizabeth Beck

Date:	09/12/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Comments:	Obesity & Thyroid Topic Discussion

View

Presentations: Peyton Elizabeth Beck

Date:	08/25/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Comments:	Topic Discussion: Hypertension Guidelines & Medications

View

Presentations: Peyton Elizabeth Beck

Date:	09/08/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Comments:	Smoking Cessation Topic Discussion

View

Presentations: Peyton Elizabeth Beck

Date:	09/09/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Comments:	On-X Products Topic Discussion

View

Presentations: Peyton Elizabeth Beck

Date:	08/18/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Comments:	Diabetes Mellitus Pharmacotherapy: Topic Discussion Presentation

View

Presentations: Peyton Elizabeth Beck

Date:	08/12/2022
Rotation Type:	P4 P6682 Advanced Community Pharmacy APPE
Comments:	Evaluation of Employee Health Programs: Financial Investment & ROI Profitability

View

Presentations: Peyton Elizabeth Beck

Date:	06/29/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Comments:	In-Service Presentation given on 06/29/22: "Psychiatric Diseases: Clinical Pearls in Pharmacotherapy"

View

Projects: Peyton Elizabeth Beck

Date:	12/15/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	El Paso Children's Hospital, Medical Rounding Team
Comments:	In-Service Presentation & Handout: Contraindicated & Precautioned Medications in the Neonatal Population

View

Projects: Peyton Elizabeth Beck
SISD_Pharmacy_Financial_Analysis_June_2021June_2022.xlsx (.xlsx) 0.28mb

Projects: Peyton Elizabeth Beck

Date:	07/06/2022
Rotation Type:	P4 P6682 Advanced Community Pharmacy APPE
Comments:	Vascepa vs. Icosapent Ethyl: Clinical Comparison

View

Projects: Peyton Elizabeth Beck

Date:	06/20/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Comments:	Created NIOSH list for the nursing staff to safely dispose unused medications in the Med Dispense room. Formatted to be put on disposal container.

View

Projects: Peyton Elizabeth Beck

Date:	06/20/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Comments:	Due to recent NIOSH updates, I recreated a site-specific HD list with risk management plan strategies.

View

Projects: Peyton Elizabeth Beck

Date:	06/20/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Comments:	ANTIMICROBIAL IV BUD and DILUENT CONCENTRATION TABLE

View

Projects: Peyton Elizabeth Beck

Date:	06/21/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Comments:	Formulary Interchangeables Report for P&T Committee

View

Projects: Peyton Elizabeth Beck

Date:	06/23/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Comments:	Updated and Reformatted Quality Assurance Checklist for the Surgery Center

View

Projects: Peyton Elizabeth Beck

Date:	06/23/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Comments:	ASC DUR Checklist for Quality Assurance

View

Projects: Peyton Elizabeth Beck

Date:	07/01/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Comments:
Comments:	Template for Renal and Hepatic Dose Adjustment Table for Continued Use & Implementation. Due to time restraints, preceptor approved "as is" submission without full completion. Preceptor planned for subsequent students to continue this project.

View

Assignments: Peyton Elizabeth Beck

Date:	11/29/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	Pediatric Drug Intervention - El Paso Children's Hospital
Patient Age:	17 Months
Patient Sex:	M
Drug-Related Needs:	effectiveness Safety
Drug Therapy Problem category:	Ineffective drug Adverse drug reaction Adherence
Assessment:	PMH: heart murmur & anomaly of chromosome pair 21 KDA: Amoxicillin Diagnosis: AR admitted on 11/26 for SOB and fever secondary to RSV (+) bronchiolitis & AOM onset. Weight: 11.6 kg Medications: Cefdinir IV x 10 days (D3/10), Albuterol 2.5 mg NEB Q3H, Miralax 8.5 g PO Daily, APAP 15 mg/kg PO SUSP Q6H PRN, Ibuprofen 10 mg/kg PO SUSP PRN, Ayr Saline 0.65% Solution 1 drop nasal TID Oxygen therapy: NC 2 - 3 L/min On 11/29 (day 3), AR is still febrile with high CRP counts. AR is also still experiencing severe respiratory symptoms due to RSV. Additionally, AR experiences an allergic reaction to Cefdinir IV therapy (severe body rash) on 11/29. Benadryl 12.5mg PO SUSP x 1 dose is given. Due to AR's allergies to amoxicillin and cefdinir, AR is in need of alternative antibiotic empiric therapy for AOM. Bacterial etiologies for AOM include Strep, H. Influenzae, and M. catarrhalis. Primary regimens for pediatric acute AOM consist of Amoxicillin, Augmentin, or Ceftriaxone x 10 days. None of these regimens are appropriate for AR due to their allergic reactions. Thus, alternative options are either Clindamycin PO (lacks H. influenzae efficacy) or Levofloxacin (not recommended in children due to joint ADEs).
Plan (Intervention, monitoring, education):	Discontinue Cefdinir IV Start Clindamycin 30-40 mg/kg/day (348-464 mg/day) PO SUSP div Q6-8H x 10 days Monitor for allergic reactions, hepatic function, GI status, and dysrhythmias due to PMH of heart murmur
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Provider Orders: Clindamycin 100 mg PO SUSP Q6H x 10 days Dosing: 34.5 mg/kg/day

Assignments: Peyton Elizabeth Beck

Date:	12/01/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	Pediatric Drug Intervention - El Paso Children's Hospital
Patient Age:	22 Months
Patient Sex:	F
Drug-Related Needs:	effectiveness
Drug Therapy Problem category:	Needs additional therapy Ineffective drug
Assessment:	PMH: recent hospitalization for bacterial pneumonia secondary to RSV(+) & Rhino (+) with Augmentin outpatient treatment upon discharge. Patient is not fully immunized. Weight: 11.7 kg Diagnosis: YB readmitted for fever secondary to bacterial pneumonia and failed outpatient Augmentin therapy. YB completed 2.5 days of Augmentin 38 mg/kg PO SUSP BID treatment before readmittance. Upon admission, RSV & Rhino still detected, as well as high WBC count, low CO2, high glucose, high protein, high bilirubin, high AST & ALT, high alk phos, and high CRP laboratory results. Medications: APAP 15 mg/kg PO Elixir Q6H PRN & MIVF For children > 3 mo, bacterial pneumonia etiologies consist of Strep (group A), H. influenzae, mycoplasma, Staph, and M. tuberculosis. The primary regimen for not fully immunized children is Ceftriaxone 75-100 mg/kg IV Daily x 10-14 days. If MRSA is suspected, add Vancomycin 60-80 mg/kg/day div Q6-8H or Clindamycin 40 mg/kg/day div Q6-8H.
Plan (Intervention, monitoring, education):	Start Ceftriaxone 75-100 mg/kg (877.5-1170 mg) IV Daily x 10-14 days Start Vancomycin 60-80 mg/kg/day (702-936 mg/day) IV div Q6-8H Monitor GI, gallbladder, pancreas, renal, & hepatic function, bilirubin counts, histamine release syndrome, and DRESS signs/symptoms
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Provider Orders: Ceftriaxone 877.5 mg IM Daily x 10 days

Assignments: Peyton Elizabeth Beck

Date:	11/29/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	Pediatric Drug Intervention - El Paso Children's Hospital
Patient Age:	16 Years
Patient Sex:	F
Drug-Related Needs:	effectiveness
Drug Therapy Problem category:	Needs additional therapy Other
Assessment:	PMH: wisdom teeth removal on 11/16 (11 days prior to admission) Diagnosis: SB admitted on 11/27 for right-sided facial cellulitis & masticatory myositis secondary to a wisdom teeth removal procedure. Weight: 37.9 kg Medications: Unasyn 50 mg/kg (1885 mg) IVPB Q6H x 10 days (start on 11/27), APAP 13 mg/kg PO PRN, Toradol 10 mg IVP Q6H x 5 days (11/27 - 12/02) On 11/29 (D2/10), SB is afebrile, but still reports "burning pain" on the right side of jaw. For facial cellulitis, the common etiologies present are Staph, Strep, and H. influenzae (in children). Regimens usually consist of Vancomycin for 7-10 days in order to treat as if MRSA is present. Suggest adding or switching to Vancomycin 60-80 mg/kg/day IV div Q6-8H x 8 days for adequate coverage until the end of therapy. Step down therapy options for potential discharge should also provide adequate empirical coverage. Options include Augmentin PO or Bactrim PO. *Once rounds occurred, the medical team decided on SB's discharge*
Plan (Intervention, monitoring, education):	Discontinue Unasyn on day 2 of 10 of therapy Discharge Start Augmentin 20-40 mg/kg/day (758-1516 mg/day) PO div Q8H x 8 days
Was your intervention or recommendation accepted by the patient/providere?:	Yes
Additional Comments:	Provider Orders: Discharge on Augmentin PO 875 mg BID x 7 days

Assignments: Peyton Elizabeth Beck

Date:	11/22/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	Pediatric Drug Intervention - El Paso Children's Hospital
Patient Age:	17 Months
Patient Sex:	M
Drug-Related Needs:	effectiveness
Drug Therapy Problem category:	Needs additional therapy Ineffective drug
Assessment:	PMH: AOM with outpatient antibiotic treatment failure Diagnosis: DE is readmitted after an AOM diagnosis for a fever and swollen eye secondary to periorbital cellulitis. Patient has recently failed Amoxicillin and Ceftriaxone therapies. Weight: 10.3 kg Medications: Unasyn 50 mg/kg IVPB Q6H, APAP 15.7 mg/kg PO SUSP PRN, MIVF DE has not made clinical improvements with Unasyn IV therapy. DE is still febrile with high WBC counts. DE's physical symptoms have also not improved with continued redness and swelling. The provider assumed DE would be stable by now for discharge with Augmentin PO and Bacitracin ointment, but that is now not the case. DE has now failed Amoxicillin, Ceftriaxone, and Unasyn antibiotic therapy. Periorbital cellulitis treatment should include coverage against S. aureus, strep, and anaerobes. Monotherapy with Augmentin or Cefdinir is not recommended due to lack of MRSA coverage. Due to DE's failed therapies, MRSA coverage is now required for adequate therapy. Additionally, DE will need a longer duration of adequate antibiotics. The usual duration is 5-7 days, but 10 days is recommended for this complexity. Current recommendations include Clindamycin or Bactrim + Augmentin or Cefdinir. For DE, Augmentin is not recommended due to recent antibiotic regimens. In comparison to Bactrim, Clindamycin has greater coverage of Strep A.
Plan (Intervention, monitoring, education):	Discontinue Unasyn 50 mg/kg (515 mg) IV Q6H Start Cefdinir 14 mg/kg/day PO div Q12-24H x 10 days Start Clindamycin 30-40 mg/kg/day PO div Q6-8H x 10 days Monitor hepatic function and GI status
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Provider's Orders: Cefdinir 7 mg/kg PO Q12H x 8 days Erythromycin 0.5% Ophthalmic Ointment 1 ribbon in affected eye Q6H

Assignments: Peyton Elizabeth Beck

Date:	11/14/2022
Rotation Type:	P4 P6686/P6687 Pt Care Elective I/II APPE
Comments:	Pediatric Drug Intervention - El Paso Children's Hospital
Patient Age:	1 Month
Patient Sex:	F
Drug-Related Needs:	Indication Safety
Drug Therapy Problem category:	Unnecessary drug therapy Adverse drug reaction
Assessment:	PMH: resolving subdural hemorrhage, hypoxic ischemic encephalopathy, increased bilirubin, and gestational diabetic pregnancy complications. ZM recently received 47 hour phototherapy. Diagnosis: Ethmoid sinus disease and respiratory distress secondary to RSV(+) bronchiolitis. ZM's symptoms consist of cough, SOB, lethargy, emesis, and nasal congestion. Oxygen therapy: NC 0.5 L/min Medications: Ceftriaxone 164 mg IV Daily and Cholecalciferol 400U PO Daily ZM has no current indications for antibiotic therapy. ZM's blood cultures are negative, and ZM's symptoms are indicative of the RSV(+) respiratory biofire results. Additionally, due to ZM's age and PMH of increased bilirubin, the use of Ceftriaxone puts them at an unnecessary risk for kernicterus - a population-specific condition resulting in brain damage from increased bilirubin secondary to Ceftriaxone use.
Plan (Intervention, monitoring, education):	Discontinue Ceftriaxone 164 mg IV Monitor: BUN, Protein, AST, ALT, bilirubin, CRP, procalcitonin
Was your intervention or recommendation accepted by the patient/provider?:	Yes

Assignments: Peyton Elizabeth Beck

Date:	08/22/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Patient Age:	77 Years
Patient Sex:	M
Patient Ethnicity:	White
What prescription(s) did you counsel on? Provide Drug Name and Dose, along with the SIG.:	Primidone 50mg Tablet Cholecalciferol 50mcg Tablet Ezetimibe 10mg Tablet Foltx (folic acid, cyanocobalamin, pyridoxine) Losartan 100mg Tablet Metformin 850mg Tablet BID Montelukast 10mg Tablet Paroxetine 40mg Tablet Semaglutide 0.5/0.375 injection Vit B Complex - Vit C Apixaban 5mg Tablet BID Carvedilol 6.25mg Tablet Famotidine 20mg Tablet Furosemide 20mg Tablet Guaifenesin 400mg Tablet ASA 81mg EC Tablet Multi-Vitamin (at home) Glucosamine (at home) Fish Oil 100mg (at home) APAP 500mg PRN (at home) Vitamin E 400U Cap (at home)
Chief Concern:	PO to NPO Formulations
The following items were discussed with the patient (select all that apply):	Medication Name Indication Dosage regimen Side Effects (common and severe) Drug Interactions Self-Monitoring (when applicable)
History of Present Illness:	DVT, NV A Fib, T2DM, HTN
Which patient counseling approach(es) did you utilize (select all that apply)?:	Verify Patient Understanding Used Patient Friendly Language Provided Opportunity for Follow-Up Questions Maintained Professionalism during Counseling
Goals of Therapy:	- Improve adherence and safety by switching from PO to NPO formulations - Minimize ADEs, bleeding risks, and drug-drug interactions
Drug-Related Needs:	Safety Adherence
Drug Therapy Problem category:	Needs additional therapy Ineffective drug Adverse drug reaction Adherence
Assessment:	*File attachment*
Plan (Intervention, monitoring, education):	Updated Regimen: - APAP PO liquid - Furosemide PO solution - ASA 81mg PO chewable - Famotidine PO suspension - Guaifenesin PO liquid - Sertraline PO solution - Semaglutide SQ injection - Apixaban PO tablets (crushed) - Ezetimibe PO tablets (crushed) - Losartan PO tablets (crushed) - Calcitonin Nasal Spray - Montelukast PO chewable / granules - Metformin PO solution - OTC Glucosamine, Chondroitin, Potassium, Vitamin C PO solution - Omega DHA OTC Gummies / Liquid - 5-MTHF Plus Folic Acid & VitB12 Quick Dissolve Cherry Tablet - Further discuss Beta-Blocker options: Carvedilol ER Sprinkle Capsules, Metoprolol Succ ER Sprinkle Capsules, Carvedilol PO tablets (crushed), or Propranolol HCl PO solution - Further discuss Anticonvulsant options: Gabapentin PO solution, Valproic Acid PO syrup, Felbamate PO suspension, Divalproex Sprinkle Capsules, Phenobarbital PO elixir, or Primidone PO tablets (crushed)
Was your intervention or recommendation accepted by the patient/provider?:	Yes

View

Assignments: Peyton Elizabeth Beck

Date:	08/24/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Patient Age:	50 Years
Patient Sex:	M
What prescription(s) did you counsel on? Provide Drug Name and Dose, along with the SIG.:	Initial Hyperlipidemia Consult
Chief Concern:	Borderline Hypertriglyceridemia - triglycerides slightly elevated at 210 mg/dL
The following items were discussed with the patient (select all that apply):	Indication Self-Monitoring (when applicable)
History of Present Illness:	WNL - HDL, LDL, TC No current medications for hyperlipidemia; no renal/hepatic complications; NKDA
Which patient counseling approach(es) did you utilize (select all that apply)?:	Verify Patient Understanding Used Patient Friendly Language Provided Opportunity for Follow-Up Questions Maintained Professionalism during Counseling
Goals of Therapy:	TG < 150 mg/dL
Drug-Related Needs:	Indication
Drug Therapy Problem category:	Unnecessary drug therapy
Assessment:	It is not necessary for pharmacological treatment at this time, since the patient is not at considerable risk for pancreatitis (TG > 500 mg/dL), and the efficacy of ASCVD protection by TG reduction is not well known. ASCVD protection is usually demonstrated with LDL-C reduction, and those are currently WNL.
Plan (Intervention, monitoring, education):	Monitoring & Recommendations: - Assess acquired factors: genetic risk factors, insulin resistance, hypothyroidism, sugar & fat consumption, excessive alcohol consumption, various medication interactions - Retest: fasting TG levels can fluctuate depending on alcohol consumption, meals, and exercise within the past 12-24 hours - Monitor: lipid profile, BG, A1C, SCr, TSH, albumin-protein, ASCVD risk factor management
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Case provided by Dr. Dean Jan

Assignments: Peyton Elizabeth Beck

Date:	09/07/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Patient Age:	30 Years
Patient Sex:	M
Patient Ethnicity:	Asian
What prescription(s) did you counsel on? Provide Drug Name and Dose, along with the SIG.:	Warfarin PO 5mg daily, except take 7.5mg every M/W/F
Chief Concern:	Post operative management and low INR; complains of bleeding in his mouth with meals
The following items were discussed with the patient (select all that apply):	Medication Name Indication Dosage regimen Duration of Therapy Side Effects (common and severe) Drug Interactions Missed Dose Instructions Self-Monitoring (when applicable)
History of Present Illness:	- Warfarin for 3 years with 3 previous in-range INR readings - Atrial fibrillation - Warfarin held for 5 days in preparation of tooth extraction & root canal - Today's reading: 1.5 INR
Which patient counseling approach(es) did you utilize (select all that apply)?:	Verify Patient Understanding Used Patient Friendly Language Provided Opportunity for Follow-Up Questions Maintained Professionalism during Counseling
Goals of Therapy:	- INR goal of 2 - 3 - Reduce gum bleeding
Drug-Related Needs:	Safety Adherence Other
Drug Therapy Problem category:	Adverse drug reaction Adherence Other
Assessment:	In range INRs --> appropriate initial dosing with 5mg T, R, Sat, Sun & 7.5mg M, W, F Held warfarin for 5 days --> significant reduction in INR expected 5 days since dental procedure and re-initiation of warfarin Currently: INR is subtherapeutic by 0.5, but there are complaints of bleeding. Due to the site and procedure, it is appropriate to reason that the bleeding isn't due to the patient's warfarin. Assess metabolic changes & signs/symptoms of DVT/PE, stroke, blood clots: new medications, over the counter medications, symptoms that affect absorption (decreased intake, diarrhea), and recent dietary changes; antibiotics can decrease/increase INR
Plan (Intervention, monitoring, education):	Based solely on INR: add 5mg to today's dose and follow up in 1-2 weeks OR do not make changes and refer patient to dental provider for bleeding consultation Potential monitoring: neuroimaging due to "head trauma"; follow-up consultation with dental & surgical provider We do not want to inconsistently change the patient's diet, but educating patient on what to look for when looking for "softer food" options (also can discuss with surgical provider)
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Case provided by Dr. Dean Jan

Assignments: Peyton Elizabeth Beck

Date:	09/22/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Patient Age:	81 Years
Patient Sex:	M
Patient Ethnicity:	Hispanic or Latino
What prescription(s) did you counsel on? Provide Drug Name and Dose, along with the SIG.:	Eliquis 5 mg PO BID
Chief Concern:	Eliquis Follow-up Consultation with Declining Renal Function
The following items were discussed with the patient (select all that apply):	Medication Name Indication Dosage regimen Duration of Therapy Side Effects (common and severe) Drug Interactions Missed Dose Instructions Self-Monitoring (when applicable)
History of Present Illness:	- Atrial fibrillation & AHD - Mild cognitive impairment & sleep disorder - Hypertension - Diabetes - Hypokalemia
Which patient counseling approach(es) did you utilize (select all that apply)?:	Verify Patient Understanding Used Patient Friendly Language Provided Opportunity for Follow-Up Questions Maintained Professionalism during Counseling
Goals of Therapy:	Protect renal function
Drug-Related Needs:	effectiveness Safety
Drug Therapy Problem category:	Dosage too high
Assessment:	- Medications currently taking: Eliquis, Furosemide, Potassium Chloride, Lisinopril, Memantine, Metoprolol Succinate, Metformin, Amlodipine, Atorvastatin, Alendronate, Ferrous Sulfate, Magnesium - Patient has normal liver function, but most recent labs indicate declining renal function with 1.5 SCr - Declining renal function may be due to Furosemide 20 mg and Potassium Chloride 10 mEq - Due to his age and SCr, it is recommended that this patient be on Eliquis 2.5 mg PO BID (2 out of 3 criteria; patient is at healthy weight)
Plan (Intervention, monitoring, education):	Reduce Eliquis dose from 5 mg PO BID to 2.5mg PO BID Order labs for next appointment Order pill-cutter
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Patient seen with Dr. Navarro

Assignments: Peyton Elizabeth Beck

Date:	09/23/2022
Rotation Type:	P4 P6684 Ambulatory Care APPE
Patient Age:	76 Years
Patient Sex:	M
Patient Ethnicity:	White
What prescription(s) did you counsel on? Provide Drug Name and Dose, along with the SIG.:	Warfarin 7.5 mg PO QD
Chief Concern:	INR > 8
The following items were discussed with the patient (select all that apply):	Medication Name Indication Dosage regimen Duration of Therapy Side Effects (common and severe) Drug Interactions Missed Dose Instructions Self-Monitoring (when applicable)
History of Present Illness:	Multiple myeloma, anemia, renal mass, mechanical valve Undergoing chemotherapy Temporarily on ertapenem therapy (finished next week) Past INR of 3.0 (2 weeks ago)
Which patient counseling approach(es) did you utilize (select all that apply)?:	Verify Patient Understanding Used Patient Friendly Language Provided Opportunity for Follow-Up Questions Maintained Professionalism during Counseling
Goals of Therapy:	2.5 - 3.5 INR goal
Drug-Related Needs:	effectiveness Safety
Drug Therapy Problem category:	Adverse drug reaction Dosage too high Adherence Other
Assessment:	- Within 2 weeks, patient's INR increased from 3.0 to > 8.0. This is INR value, it is recommended to go to lab to get second INR reading for potential Vitamin K therapy. - Patient refuses to go to lab - Patient is currently asymptomatic - Holding one dose of warfarin predicts INR dropping by a value of 1. If patient holds for 3 days, INR is expecting to drop below 4.
Plan (Intervention, monitoring, education):	Hold Warfarin for 3 consistent days, starting with today (Friday, Saturday, Sunday). Reinitiate 7.5 mg PO QD on Monday (09/26). Follow up appointment in 1 week (09/29).
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Patient seen with Dr. Miller

Assignments: Peyton Elizabeth Beck

Date:	08/03/2022
Rotation Type:	P4 P6682 Advanced Community Pharmacy APPE
Patient Age:	65 Years
Patient Sex:	M
Patient Ethnicity:	White
Drug-Related Needs:	Indication effectiveness
Drug Therapy Problem category:	Needs additional therapy Ineffective drug
Assessment:	- Current medications: Metformin 1000mg BID, Metoprolol Succinate XR 50mg, Terazosin 10mg, Cetirizine 10mg - Patient has complained of night-time urination and erectile dysfunction development; patient has a history of T2DM and HTN - Due to the patient's age, weight, and history of diabetes, the patient should be evaluated for benign prostatic hyperplasia (BPH) - BPH: urinary incontinence, enlarged prostate, lower urinary tract symptoms
Plan (Intervention, monitoring, education):	- Discontinue Terazosin - Initiate Tadalafil 5mg PRN and Tamsulosin 0.4mg Daily - Monitor PSA, PVR urine test, and urinary flow rate - If no improvement is seen with Tamsulosin, consider dual therapy with Finasteride
Was your intervention or recommendation accepted by the patient/provider?:	Yes

Assignments: Peyton Elizabeth Beck

Date:	08/02/2022
Rotation Type:	P4 P6682 Advanced Community Pharmacy APPE
Patient Age:	41 Years
Patient Sex:	M
Patient Ethnicity:	Hispanic or Latino
Drug-Related Needs:	effectiveness Adherence
Drug Therapy Problem category:	Needs additional therapy Ineffective drug Adherence
Assessment:	- Current medications: Losartan/HCTZ 100-25mg, Metformin 1000mg BID, Amlodipine 10mg, Naproxen 500mg BID PRN - Prescriber switched patient from Lisinopril 40mg Daily to Losartan/HCTZ 100-25mg - Amlodipine and Lisinopril were already at maximum daily dose - Guideline algorithm: ACE-I or ARB +/- CCB ---> + thiazide-like diuretic ---> resistant HTN - 1-2 titration steps are recommended before modifying or adding a medication; evaluation of adherence and proper BP evaluation is imperative - Benefits for thiazide-like diuretics: osteoporosis, edema, and calcium nephrolithiasis with hypercalciuria; diuretics should be given for volume control in patients with heart failure or chronic kidney disease, with or without nephrotic syndrome; these settings usually require loop diuretics - Patient is now at maximum dose for combined Losartan/HCTZ
Plan (Intervention, monitoring, education):	- Continue Losartan/HCTZ 100-25mg for 4 weeks --> if blood pressure remains uncontrolled, discontinue combination to increase HCTZ dose to 50mg --> if BP remains uncontrolled, consider chlorthalidone or indapamide over HCTZ. - If patient has severely increased albuminuria, consider diltiazem or verapamil over amlodipine - Monitor: blood pressure, ACR, kidney function, heart rate, edema, potassium, sodium, calcium - Educate on lifestyle interventions to lower BP - Reassess 2-4 weeks after initiation or titration of therapy
Was your intervention or recommendation accepted by the patient/provider?:	Yes

Assignments: Peyton Elizabeth Beck

Date:	05/25/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Patient Age:	54 Years
Patient Sex:	F
Patient Ethnicity:	Hispanic or Latino
Drug-Related Needs:	effectiveness Safety
Drug Therapy Problem category:	Unnecessary drug therapy Needs additional therapy Dosage too low Adverse drug reaction
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Provider changed APAP tablets to Ibuprofen tablets.

View

Assignments: Peyton Elizabeth Beck

Date:	06/01/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Patient Age:	78 Years
Patient Sex:	M
Patient Ethnicity:	Hispanic or Latino
Chief Concern:	Inappropriate Vancomycin regimen for C-diff induced sepsis
Drug-Related Needs:	effectiveness
Drug Therapy Problem category:	Dosage too low
Plan (Intervention, monitoring, education):	Discontinue Vancomycin 125 mg via GT Q6H x 14 days Initiate Vancomycin C-diff pulse taper regimen
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Provider changed Vancomycin regimen to: 125 mg PO Q6H x 14 days 125 mg PO Q8H x 7 days 125 mg PO Q12H x 7 days 125 mg PO Q24H x 7 days 125 mg PO Every Other Day x 7 days 125 mg PO Q72H x 7 days

View

Assignments: Peyton Elizabeth Beck

Date:	06/02/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Patient Age:	78 Years
Patient Sex:	M
Patient Ethnicity:	Hispanic or Latino
Drug-Related Needs:	effectiveness
Drug Therapy Problem category:	Dosage too low
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Provider changed Lovenox dose from 100 mg SubQ daily to 90 mg SubQ BID

View

Assignments: Peyton Elizabeth Beck

Date:	06/08/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Patient Age:	63 Years
Patient Sex:	M
Patient Ethnicity:	Hispanic or Latino
Chief Concern:	Reassessment of LMW Heparin Therapy for Patient with AKI and Dialysis
Drug-Related Needs:	Safety
Drug Therapy Problem category:	Adverse drug reaction
Plan (Intervention, monitoring, education):	Discontinue Lovenox 40 mg SC Q12H Initiate Heparin 5000U SC Q8-12H
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Provider changed Lovenox to Heparin 5000U SC Q12H

View

Assignments: Peyton Elizabeth Beck

Date:	06/13/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Patient Age:	73 Years
Patient Sex:	M
Patient Ethnicity:	Hispanic or Latino
Chief Concern:	Uncontrolled T2DM
Drug-Related Needs:	effectiveness
Drug Therapy Problem category:	Dosage too low Dosage too high
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Provider changed Levemir to 20U with taper in mind to control blood glucose

View

Assignments: Peyton Elizabeth Beck

Date:	06/29/2022
Rotation Type:	P4 P6683 Advanced Hosp/Hlth Sys Pharm APPE
Patient Age:	80 Years
Patient Sex:	M
Patient Ethnicity:	Hispanic or Latino
Chief Concern:	Nonoptimal Vancomycin Dosing for Vertebral Osteomyelitis
Drug-Related Needs:	effectiveness
Drug Therapy Problem category:	Needs additional therapy Ineffective drug Dosage too low
Plan (Intervention, monitoring, education):	Initiate Vancomycin 750 mg IV Q12H with stop date between 08/05 - 08/19 Discontinue Meropenem 1 gram IV Q8H Initiate Cephalosporin: Ceftriaxone 2 grams IV Daily or Cefepime 2 grams IV Q12H
Was your intervention or recommendation accepted by the patient/provider?:	Yes
Additional Comments:	Provider changed Vancomycin dose to 750 mg IV Q12H

View

Assignments: Peyton Elizabeth Beck

Date:	01/07/2022
Rotation Type:	P3Su P6281 Hospital Course IPPE
What are benefits to dispensing methods?	Easy and quicker access to medications, maintaining accurate inventory
What are the limitations to that dispensing method?	Out-of-stock situations, increased requirements and procedures for inventory maintenance, increased time and labor to maintain inventory and stock levels. Certain drugs may go unused and pass its expiration date.
List and describe a dispensing method used in Hospital Practice:	Storage-based dispensing: Omnicell machines - stocks of medications in secure, centralized locations that restrict access to authorized personnel.
List and describe a dispensing method used in Hospital Practice:	Tray-based dispensing - medication prep trays are used to dispense multiple medications to one workstation. The trays are designed for different needs and/or conditions, such as 'crash carts', anesthesia, and epidural trays.
What is the benefit(s) to that dispensing method?	Quicker, more efficient method to access medications. Reduce time for storage restocking time with swapping individual medications.
What are the limitations to that dispensing method?	Re-stocking trays may be tedious and time-consuming. Increased time necessary for pharmacists to manually check and verify. Inaccurate restocking and inventory errors is possible. Certain medications may go unused and pass its expiration date.
List and describe a dispensing method used in Hospital Practice:	Pneumatic tube system delivery - 'tubes' used to secure medications and transport items over any distance in hospital to desired workstation.
What is the benefit(s) to that dispensing method?	Fast transportation of medications over long distance. Medications stay secure when traveling. No labor or time necessary to deliver medications.
What are the limitations to that dispensing method?	Certain medications cannot be dispensed through tube system (controlled substances, hazardous medications, expensive medications). When medication is delivered by tube to workstation, anyone with access can take medication. Decreased security of medication upon arrival could lead to medication errors and inventory discrepancies.

Assignments: Peyton Elizabeth Beck

Date:	01/12/2022
Rotation Type:	P3Su P6281 Hospital Course IPPE
Describe an inventory management principle used at your site:	Assessment of supply chain data in automated systems
Describe any benefit(s) to using this inventory management principle:	Prevents surpluses and shortages; more efficient purchasing; saves money by cutting waste and reducing drug expiration problems
Describe any limitation(s) to using this inventory management principle:	Time and money for logistic analyses; regulatory pressures with accurate forecasting; hospital needs are more challenging to predict based on vastness of conditions and populations
Describe an inventory management principle used at your site:	Corporate contracts and formulary
Describe any benefit(s) to using this inventory management principle:	Efficient formulary saves money on unnecessary medications; reduce healthcare costs; authorized substitutions leads to saving time when provider sends order for non-formulary products
Describe any limitation(s) to using this inventory management principle:	Strong institutional/regulatory pressures; safety stock leads to high operational cost and drug expirations; corporate compares MMC's costs to others within their company, even though other locations do not have a cancer center. This causes corporate to be extra conservative with the formulary and authorizations at MMC because of its high costs with the cancer center.
Describe any benefit(s) to using this inventory management principle:	Stock what hospital needs without the cost and risk of surplus/expiration; tracks RFID-tagged products securely; invoices only what is used with automatic reordering; continuous temperature, recall, and expiration monitoring
Describe any limitation(s) to using this inventory management principle:	Sensitive system - if someone pulls a product, it will automatically be notified and invoiced; may not have all product needs available to stock due to consignment contracts; time and money for installation and technical support; training required; third party procedures
Describe an inventory management principle used at your site:	Utilization of Cubixx refrigerators - "safety stock" with consignment services that eliminate cost of expensive and uncertain drug supplies

Assignments: Peyton Elizabeth Beck

Date:	01/12/2022
Rotation Type:	P3Su P6281 Hospital Course IPPE
List/describe a strategy used to address the drug's shortage:	Change dosage form from IV to PO; if able, change dosage form to IVPB to IVP
List/describe any barriers/challenges to addressing this drug's shortage:	NPO patients; potential ADEs with drug alternatives; more time and effort to administer IVP, making it harder on nurses
What is the name of a drug that is currently on shortage?	Famotidine IV
What is the name of a drug that is currently on shortage?	Levofloxacin IV
List/describe a strategy used to address the drug's shortage:	Change from IV to PO; authorized alternatives (ciprofloxacin, moxifloxacin)
List/describe any barriers/challenges to addressing this drug's shortage:	NPO patients; potential ADEs with drug alternatives; usually used in combination with metronidazole - affecting preferred combination therapies
What is the name of a drug that is currently on shortage?	Metronidazole IV
List/describe a strategy used to address the drug's shortage:	IV to PO; authorized alternatives for anaerobic coverage or broad-spectrum coverage (clindamycin, amoxicillin-clavulanate, Zosyn)
List/describe any barriers/challenges to addressing this drug's shortage:	NPO patients; potential ADEs with authorized alternatives; affects preferred combination therapies

Assignments: Peyton Elizabeth Beck

Date:	02/20/2022
Rotation Type:	P3S P6255 Pharm Mgmt/ P6135 Spanish

View

Assignments: Peyton Elizabeth Beck

Date:	05/03/2022
Rotation Type:	P3F P6345 ECHO Pharm

View

Reviews & Evaluations: Peyton Elizabeth Beck
Completed by Dr. Janice Miller, El Paso VA Healthcare System Ambulatory Care APPE Final Evaluation (.pdf) 0.60mb

Reviews & Evaluations: Peyton Elizabeth Beck
Completed by Dr. Eric Garcia, SISD Employee Health Clinic Community APPE Final Evaluation (.pdf) 0.58mb

Reviews & Evaluations: Peyton Elizabeth Beck
Completed by Dr. Mikhil Adusumilli, Premier Specialty Hospital Hospital APPE Final Evaluation (.pdf) 0.54mb

Capstone: Peyton Elizabeth Beck

COVID Synergy: A Machine Learning Approach Uncovering Potential Treatment Combinations for SARS-CoV-2
Project Contributors: Sirimulla S, Sanchez J, Beck P, Corella V, Omoegbele E

Quantitative, inductive research aimed at developing a machine learning model to predict synergistic drug combinations against SARS-CoV-2 in silico with in vitro validation

MIT License obtained for Copyright © 2020 Sirimulla Research Lab; CAPStone faculty approved May 2022

Capstone Poster Presentation (.pdf) 0.79mb

Research Experience & Interests: Peyton Elizabeth Beck

Texas Tech University Health Sciences Center at El Paso, Emergency Medicine and Clinical Sciences 
Project Contributors: Michelson E, Lawati ZA, Watts S, Lange R, Monks S, Rodriguez L, Beck P, Marquez L, Pinon AT, Kariyawasam DE

Evaluate altered brain electrical activity in COVID patients with use of Brainscope One device to find similarities seen in concussion patients

IRB approved February 2022; Sponsored by Brainscope Company, Inc.

Research Experience & Interests: Peyton Elizabeth Beck

Texas Tech University Health Sciences Center at El Paso, Emergency Medicine and Clinical Sciences 
Project Contributors: Michelson E, Nordquist E, Watkins S, Watts S, Monks S, Lange R, Rodriguez L, Beck P, Marquez L, Pinon AT, Kariyawasam DE

Evaluate the effectiveness of repurposed medications in reducing symptoms for non-hospitalized participants with mild to moderate COVID-19

IRB approved September 2021; Sponsored by National Center for Advancing Translational Sciences

Research Experience & Interests: Peyton Elizabeth Beck

Texas Tech University Health Sciences Center at El Paso, Emergency Medicine and Clinical Sciences
Project Contributors: Michelson E, Nordquist E, Miller J, Watkins S, Watts S, Weber N, Monks S, Rodriguez L, Marquez L, Beck P, Pinon AT, Kariyawasam DE

Evaluating the efficacy of cromolyn, in combination with standard COVID-19 treatment, on patient oxygenation, respiratory symptoms, hospitalization stay duration, oxygen supplementation time, and days to improved QoL

IRB approved August 2021; Sponsored by National Center for Advancing Translational Sciences

Research Experience & Interests: Peyton Elizabeth Beck

Texas Tech University Health Sciences Center at El Paso, Emergency Medicine and Clinical Sciences
Project Contributors: Michelson E, Watts S, Monks S, Weber N, Rodriguez L, Marquez L, Beck P, Pinon AT, Kariyawasam DE

Validate the clinical accuracy of a negative Structural Injury Classifier (SIC) evaluation, in order to add confidence in physicians’ decisions to not order head CT scans when SIC evaluations are used as an additional measure in the clinical evaluation for the necessity of head CT scans

IRB approved May 2020; Sponsored by Brainscope Company, Inc.

Research Experience & Interests: Peyton Elizabeth Beck

Texas Tech University Health Sciences Center at El Paso, Emergency Medicine and Clinical Sciences
Project Contributors: Michelson E, Monks S, Watts S, Weber N, Rodriguez L, Beck P, Pinon AT, Marquez L, Kariyawasam DE

Evaluate the safety and efficacy of the Tbit system in an emergent setting when used on adult patients undergoing Cranial Computerized Tomography (CCT) scans; the objective is to evaluate the Tbit system’s ability to predict positive and negative CCT results regarding TBI presence

IRB approved December 2019; Sponsored by BioDirection, Inc.

Research Experience & Interests: Peyton Elizabeth Beck
Texas Tech University Health Sciences Center at El Paso, Emergency Medicine and Clinical Sciences
Project Contributors: Michelson E, Watts S, Weber N, Rodriguez L, Beck P, Marquez L, Pinon AT, Kariyawasam DE

Evaluate the diagnostic and prognostic performances of the Inflammatix HostDx Sepsis test to diagnose bacterial and viral infections by using endpoints of ICU-level care within 7 days, 5 days, and 28-day mortality

IRB approved November 2019; Sponsored by Inflammatix

Teaching Experience: Peyton Elizabeth Beck

January 2022
Student Society of Health-System Pharmacists (SSHP) Wellness Committee
University of Texas at El Paso School of Pharmacy

Prepared one-hour lesson for UTEP pharmacy students about the benefit of organizational strategies in a doctoral program and their influences on success, productivity, and well-being

Organization Presentation Slides (.pdf) 1.77mb

Teaching Experience: Peyton Elizabeth Beck

December 2021
Student Society of Health-System Pharmacists (SSHP) Wellness Committee
University of Texas at El Paso School of Pharmacy

Prepared one-hour activity for UTEP pharmacy students to practice reflective journaling and how to implement these practices in self-care routines 

Teaching Experience: Peyton Elizabeth Beck

November 2019
Culture, Literacy, and Community Health Course, UTEP School of Pharmacy
Mesita Elementary School – El Paso, TX

Presented to elementary school students about the important aspects of OTC drug labels and how to identify them

Association & Society Membership: Peyton Elizabeth Beck

April 2021 – Present
Epsilon Kappa Chapter 
President (2022 - 2023)
President-Elect (2021 - 2022)

Association & Society Membership: Peyton Elizabeth Beck

April 2021 – Present
Epsilon Phi Chapter
President (2022 - 2023)
Vice-President (2021 - 2022) 
Founding Charter Member for Establishment (2021)

Association & Society Membership: Peyton Elizabeth Beck

May 2020 – Present 
Operation Substance Abuse Chair (2022 - 2023)

Association & Society Membership: Peyton Elizabeth Beck

September 2019 – Present
Member of Wellness Committee (2021 - 2022)
P3 Class Liaison (2021 - 2022)

Association & Society Membership: Peyton Elizabeth Beck
September 2020 - August 2021
P2 Class Liaison (2020 - 2021)

Association & Society Membership: Peyton Elizabeth Beck
October 2022 - Present

Association & Society Membership: Peyton Elizabeth Beck
January 2022 – Present

Association & Society Membership: Peyton Elizabeth Beck
November 2019 – Present
El Paso Area Society of Health-System Pharmacists (EPASHP)

Honors & Awards: Peyton Elizabeth Beck
October 2022

Honors & Awards: Peyton Elizabeth Beck
April 2022

Honors & Awards: Peyton Elizabeth Beck
February 2022 Press Release for Grant Recipients (.pdf) 0.18mb

Honors & Awards: Peyton Elizabeth Beck
August 2021

Honors & Awards: Peyton Elizabeth Beck
May 2021

Athletics: Peyton Elizabeth Beck

El Paso Surf Soccer Club              
April 2020 – November 2021
Women’s Premier Soccer League (WPSL)
Pac South Conference - Desert Division

Captain of Semi-Professional Soccer Team (2021 Season)

WPSL Conference Teams Announced

Athletics: Peyton Elizabeth Beck

Wagner College Women’s Soccer              
July 2015 – May 2019
Northeast (NEC) Conference

Captain of Division I Women’s Collegiate Team (2018 Season)

Wagner Soccer Profile Link

Co-Curricular Activities: Peyton Elizabeth Beck

Date:	02/05/2021
Rotation Type:	Special Event IPPE
Comments:	COVID Vaccine Clinic Documentation

View

Co-Curricular Activities: Peyton Elizabeth Beck
Tier 3 Activity, January 2020 View

Co-Curricular Activities: Peyton Elizabeth Beck

Tier 3 Activity, January 2022

220429073445_Getting_Organized_CC_Attendance_Verification_1_27_2022_Tier_3.1_1_.pdf (.1_1_) 0.58mb

Co-Curricular Activities: Peyton Elizabeth Beck
Tier 2 Activity, November 2021 Event Reflection (.pdf) 0.03mb

Co-Curricular Activities: Peyton Elizabeth Beck
Tier 2 Activity, October 2021 Event Reflection (.pdf) 0.03mb

Co-Curricular Activities: Peyton Elizabeth Beck

Tier 1 Activity, April 2022

Event Verification Form (.2021Final_2) 0.25mb

Co-Curricular Activities: Peyton Elizabeth Beck
Tier 1 Activity, May 2020 Event Reflection (.pdf) 0.04mb

Co-Curricular Activities: Peyton Elizabeth Beck
Tier 1 Activity, October 2020 View

Co-Curricular Activities: Peyton Elizabeth Beck
Tier 1 Activity, February 2020 View

Co-Curricular Activities: Peyton Elizabeth Beck
Tier 1 Activity, October 2019 VERIFICATION OF ATTENDANCE

EVENT REFLECTION (.pdf) 0.03mb

Volunteer, Community & Civic Activity: Peyton Elizabeth Beck

Fundraising Raffle - Organizer (March 2022)
Silent Auction - Organizer (October 2021)
Homecoming Booth - Organizer (October 2021)

Volunteer, Community & Civic Activity: Peyton Elizabeth Beck

ACPE Site Visit - Volunteer Student Representative (April 2021)
Prospective Student Panels - Volunteer Student Representative (October 2019 – October 2021)

Volunteer, Community & Civic Activity: Peyton Elizabeth Beck

Student Society of Health-Systems Pharmacists (SSHP)
April 2022

Volunteer, Community & Civic Activity: Peyton Elizabeth Beck

Sara McKnight Transitional Living Center - Volunteer (September 2019 – October 2019)
Sara McKnight TLC’s Halloween Bash - Organizer (October 2019)

Languages Spoken / Skills: Peyton Elizabeth Beck
Studied for 4 years
Limited working proficiency
Pharmacy Intern in a bilingual community along El Paso-Mexican border

Languages Spoken / Skills: Peyton Elizabeth Beck

Summer student exchange program (Lünen, Germany, 2014)
Studied for 8 years
Limited working proficiency 

Licenses & Certifications: Peyton Elizabeth Beck
Texas State Board of Pharmacy Intern License (.pdf) 0.44mb

Licenses & Certifications: Peyton Elizabeth Beck
May 2021 - May 2023, American Heart Association BLS Certification (.pdf) 0.08mb

Licenses & Certifications: Peyton Elizabeth Beck
May 2022, American Pharmacists Association (APhA) MTM Certificate (.pdf) 0.48mb

Licenses & Certifications: Peyton Elizabeth Beck
July 2020, American Pharmacists Association (APhA) Immunization Certificate (.pdf) 0.13mb

Licenses & Certifications: Peyton Elizabeth Beck

Texas Tech University of Health Sciences Center at El Paso, Institutional Affiliation
Clinical Research Coordinator (CRC) 02/2022
Conflict of Interest 02/2022
Good Clinical Practice Course 02/2022
Human Subjects Research Course 02/2022

University of Texas at El Paso, Institutional Affiliation
Biomedical Researchers (Faculty and Students) 05/2022
Health Information Privacy and Security for Biomedical Researchers 05/2022
Biomedical Science Responsible Conduct of Research 10/2020

CITI Program Records (.pdf) 0.24mb

Licenses & Certifications: Peyton Elizabeth Beck
February 2022, Mayo Clinic Laboratories

Licenses & Certifications: Peyton Elizabeth Beck
May 2022 - May 2023
Missouri Board of Pharmacy